CLOPIDOGREL (Plavix)

1.0 Classification
   • Platelet aggregation inhibitor

2.0 Mechanism of Action
   • Irreversible blockade of adenosine diphosphate (ADP) receptor on platelet cell membranes, inhibiting platelet aggregation

3.0 Indications
   • Acute coronary syndrome (STEMI)

4.0 Contraindications
   • Hypersensitivity
   • Active pathological bleeding

5.0 Precautions
   • Administer with caution in patients on another platelet inhibitor

6.0 Route
   • May be given PO

7.0 Dosage
   • As part of pre-hospital fibrinolysis: 75mg for patients 75 years old and above; 300mg for patients less than 75 years old
   • For direct-to-PCI patients: 300mg

8.0 Supplied
   • 75mg and 300mg tablets

9.0 May Be Given By
   • PCP/ICP/ACP/CCP

10.0 Adverse effects
   • Bronchospasm
   • Increased risk of bleeding
   • Fever
   • Neutropenia
   • Thrombocytic Thrombocytopenic Purpura (TTP)

11.0 Special notes
   • There is an increased risk of bleeding when clopidogrel is administered in conjunction with NSAIDs
   • Pregnancy category C [if the patient will benefit from a Category C drug, it is generally used]

12.0 References